SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SoFi Technologies, Inc. is a financial service platform, which engages in the provision of student loan refinancing options to the private student loan market. It operates through the following segments: Lending, Technology Platform, and Financial Services. The Lending segment offers personal loans, student loans, home loan products, and related servicing activities. The Technology Platform segment focuses on technology products and solutions revenue. The Financial Services segment includes the SoFi Money product, SoFi Invest product, SoFi Credit Card product, SoFi Relay personal finance management product, and other financial services such as lead generation and content for other financial services institutions. The company was founded in 2011 and is headquartered in San Francisco, CA.

SoFi Technologies Inc

SoFi Technologies is experiencing significant volatility and downward pressure as investors navigate a combination of bearish short-seller reports and broader macroeconomic concerns. The community remains deeply divided, with some actively accumulating shares during the dip based on insider buying, while others express frustration over persistent share dilution and the stock's failure to maintain momentum alongside the broader market.

Ondas, Inc. engages in the development, marketing, and sale of wireless radio systems for secure, wide area mission-critical business-to-business networks. It operates through the Ondas Networks and Ondas Autonomous Systems segments. The Ondas Networks segment provides wireless connectivity solutions enabling mission-critical Industrial Internet applications and services. The Ondas Autonomous Systems segment designs, develops, and markets commercial drone solutions via the Optimus System and Scout System. The company was founded on December 22, 2014 and is headquartered in West Palm Beach, FL.

Ondas Inc.

Ondas Inc

Ondas Inc. is seeing intense investor focus fueled by a flurry of strategic acquisitions, including Rotron Aerospace and 4M Defense, alongside a high-profile partnership with Palantir that has bolstered its status as an emerging defense prime. While the stock experiences significant intraday volatility and selling pressure attributed to warrant-related hedging, the community remains heavily bullish, fixated on the upcoming earnings report and the company's potential to secure major government defense contracts in an increasingly autonomous and drone-centric global threat landscape.

The Trade Desk, Inc. engages in the provision of a self-service and cloud-based ad-buying platform. It operates through the United States and International geographical segments. The firm offers omnichannel advertising, audience targeting, solutions for identity, application programming interface (API), custom, and programmatic, measurement and optimization. The company was founded by Jeffrey Terry Green and David Pickles in November 2009 and is headquartered in Ventura, CA.

Trade Desk Inc - Ordinary Shares - Class A

Trade Desk Inc

Trade Desk is experiencing extreme volatility driven by a massive insider share purchase by the CEO and growing investor anticipation regarding a potential partnership with OpenAI. The community remains deeply divided, with some traders viewing these catalysts as a long-term bottoming signal, while others criticize the company's executive compensation and struggle to reconcile the positive news with the stock's persistent intraday sell-offs.

Swarmer, Inc. is an AI-driven software company, which develops software platforms and AI systems for autonomous swarm control of drones and unmanned vehicles. The firm offers STYX AI Command and Control System, MINAS Autonomy and Collaboration AI, and TRIDENT Embedded Drone Operating System. The company was founded by Alex Fink and Serhii Kuprienko in May 2023 and is headquartered in Austin, TX.

Swarmer Inc.

Swarmer Inc. is experiencing a volatile and high-momentum market debut as investors speculate on its drone autonomy software, which has gained attention for its reported real-world combat application. The community remains sharply divided, with some betting on a parabolic "low-float" squeeze driven by defense industry demand, while others caution against potential hype-driven instability and speculative valuations.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

TG Therapeutics is trending as the community highlights recent long-term clinical data showing Briumvi's high efficacy and record-low relapse rates, fueling speculation about potential buyouts or increased market share. Investors are actively discussing the stock's growth potential versus its current price suppression, while closely watching for upcoming earnings and subcutaneous treatment updates.

Credo Technology Group Holding Ltd. engages in the development of connectivity solutions and products for the data infrastructure market. Its products include integrated circuits, active electrical cables, and SerDes chiplets. The company was founded by Chi Fung Cheng and Yat Tung Lam on 2008 and is headquartered in George Town, Cayman Islands.

Credo Technology Group Holding Ltd

Credo Technology is facing heightened volatility as traders weigh strong product milestones in AI data center infrastructure against recent insider selling and broader market rotation out of high-growth semiconductor plays. The community is actively debating the stock's future, with many interpreting recent sharp price swings as manipulative shakeouts while bulls focus on the company's long-term potential in AI connectivity.

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Lilly(Eli) & Co

Eli Lilly is trending as investors weigh strong demand for its GLP-1 franchise against intense market competition and analyst downgrades regarding valuation and addressable market size. The community remains highly focused on the company's upcoming pipeline catalysts, specifically the anticipated approval of its oral weight-loss drug, while debating whether recent share price volatility represents a buying opportunity or a correction from previous overvaluation.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Compute and Networking Business Unit (CNBU), Mobile Business Unit (MBU), Embedded Business Unit (EBU), and Storage Business Unit (SBU). The CNBU segment includes memory products and solutions sold into client, cloud server, enterprise, graphics, and networking markets. The MBU segment is involved in memory and storage products sold into smartphone and other mobile-device markets. The EBU segment focuses on memory and storage products sold into automotive, industrial, and consumer Markets. The SBU segment consists of SSDs and component-level solutions sold into enterprise and cloud, client, and consumer storage markets. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron Technology is rallying toward all-time highs as investors pile in ahead of quarterly earnings, driven by intense demand for high-bandwidth memory (HBM) and recent announcements regarding significant manufacturing expansions in Taiwan. The community is heavily focused on the company's critical role in the AI infrastructure supply chain, with active debates centered on whether the stock remains undervalued despite its massive run or if it faces a potential post-earnings pullback.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

Nebius Group is trending following a massive $27 billion AI infrastructure deal with Meta, which effectively cements its status as a leading hyperscaler. While the stock initially surged, it faced downward pressure due to the announcement of a $3.75 billion convertible senior notes offering, sparking intense debate among investors over whether the move represents necessary capital-intensive growth or dilutive overreach.

Talon Metals Corp. engages in the exploration and development of mineral properties. It holds interests in the Tamarack nickel-copper-cobalt and Trairão iron projects. The company was founded on April 5, 2005 and is headquartered in Road Town, British Virgin Islands.

Talon Metals Corp

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Merck reportedly edged out another bidder in late-stage talks that could lead to a deal announcement as soon as Friday.</li><li>Cidara’s CD388 flu antibody, now in phase 3 trials with FDA breakthrough status, has driven significant takeover interest.</li><li>Retail traders debated whether the move signals a full buyout or a milestone-based deal structure.</li></ul><p>Cidara Therapeutics’ shares surged 42% after hours on Thursday following reports that Merck is close to acquiring the biotech in a deal that could be announced as soon as Friday.&nbsp;</p><p>The negotiations reportedly extended late into Thursday as Merck competed with another pharmaceutical group before the seller ultimately favored its offer. The deal is expected to value Cidara above its roughly $3.3 billion market capitalization, though the final price has apparently not been set. Any agreement is likely to include upfront cash and milestone-based payments tied to clinical progress, according to a&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.ft.com/content/743e1962-3dd1-4785-a20b-4b097e5514ae">report</a> by Financial Times.</p><h2 class="st-heading-2"><strong>Big Pharma Races To Rebuild Pipelines</strong></h2><p>A potential takeover would mark Merck’s latest move to fortify its drug portfolio before Keytruda, its $25 billion-per-year cancer therapy, loses patent protection in 2028. The company agreed in July to buy respiratory drug developer Verona Pharma for $10 billion as part of a broader effort to maintain revenue momentum. The demand for Cidara comes after another big-name auction last week, when&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/novo-nordisk-loses-metsera-bidding-war-to-pfizer-but-retail-traders-aren-t-losing-faith/cLPcRJWREci">Pfizer narrowly won a race against Novo Nordisk</a> for obesity biotech Metsera in a deal worth as much as $10 billion.</p><h2 class="st-heading-2"><strong>Biotech Sector Heats Up As M&amp;A Wave Accelerates</strong></h2><p>The race for Cidara is unfolding amid a surge in biotechnology dealmaking.&nbsp;<a href="https://stocktwits.com/symbol/XBI">The XBI biotech index</a> has gained over 40% in the past six months as investors bet on a return of acquisitions by big drugmakers looking to add next-generation therapies to their pipelines. The scramble reflects rising urgency across the sector as companies face major revenue losses once key products lose exclusivity.</p><h2 class="st-heading-2"><strong>Cidara’s Lead Flu Antibody Drives Takeover Expectations</strong></h2><p>Cidara’s value surge is tied to its lead program, CD388, a long-acting antibody intended to protect against the two most common strains of influenza. The treatment is being evaluated in phase 3 trials among immunosuppressed patients who cannot receive vaccines, as well as healthy adults over 65. Over 6,000 patients are expected to be enrolled in the studies worldwide by the end of the month. CD388 has been granted an&nbsp;FDA breakthrough designation, which could accelerate regulatory approval. Cidara’s shares have quadrupled since July, driven by strong clinical data and takeover speculation that have fueled investor expectations.</p><h2 class="st-heading-2"><strong>Stocktwits Buzz Highlights Takeover Speculation</strong></h2><p>On Stocktwits, retail sentiment was ‘extremely bullish’ for Cidara and ‘bullish’ for Merck, with both stocks seeing ‘high’ message volume.</p><p>One user reacted to the report by saying, “sounds like $MRK going in for the kill.”</p><p><stembedurl>https://stocktwits.com/JFais/message/636148828</stembedurl></p><p>Another user questioned the structure of the potential deal, writing, “It makes me wonder if it is an actual buyout or an investment in the company for rights to their drug? It mentions the possibility of upfront cash plus milestone payments.... hopefully it is a buyout above the current $150 AH price.”</p><p><stembedurl>https://stocktwits.com/PooPooPewPew/message/636148400</stembedurl></p><p>While&nbsp;<a href="https://stocktwits.com/symbol/CDTX">Cidara’s stock</a> has surged 446% so far in 2025,&nbsp;<a href="https://stocktwits.com/symbol/MRK">Merk’s stock</a> has risen 18% over the same period.</p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

In this photo illustration, the Cidara Therapeutics logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Cidara Therapeutics Stock Soars 42% After-Hours On Merck Buyout Buzz — Retail Traders Eye A Potential Blowout Premium

Merck reportedly edged out another bidder in late-stage talks that could lead to a deal announcement as soon as Friday.

Equity

Merck Rises 13% in a Week: Should You Buy, Sell or Hold the Stock?

MRK's stock witnesses an upside after Pfizer's pricing deal, but Gardasil's slump and Keytruda's looming LOE keep investors cautious.

Merck Falls 14% YTD: Time to Buy, Sell or Hold the Stock?

Merck stock is down 14% this year as Keytruda-led growth gets offset by Gardasil weakness and looming patent risks, which cloud the outlook.

All You Need to Know About Verona Pharma (VRNA) Rating Upgrade to Buy

Verona Pharma (VRNA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Merck's Narrowed 2025 Sales View: What it Means After Q2 Results?

MRK trims its 2025 sales range but lifts the lower end of its EPS outlook. Keytruda, Animal Health and new drugs are expected to drive a second-half rebound.

Merck Stock Down 4% Since Q2 Results: How to Play the Stock

Merck slips following its Q2 results as Gardasil sales slump. However, Keytruda, new launches and a rich pipeline bolster its long-term case.

Volatility-Proof Your Portfolio With VIPS, GDS, FUTU & VRNA Stocks 

Shield your portfolio from market swings with low-beta picks like VIPS, GDS, FUTU and VRNA, each showing strong momentum.

Merck Unveils Cost-Cutting Plan: Can it Create Long-Term Value?

MRK targets $3B in annual savings by 2027 as it cuts jobs and refocuses investment ahead of Keytruda's 2028 patent cliff.

Merck Q2 Earnings Top, Sales Meet Estimates, 2025 View Narrowed

MRK beats second-quarter estimates for EPS while matching the same for sales. The company trims its 2025 outlook.

Merck Q2 Earnings in the Cards: Buy, Sell or Hold Ahead of Results?

MRK is gearing up to report Q2 earnings. While Keytruda drives growth, there are concerns over Gardasil's China sales, generics and pipeline depth. 

Verona Pharma Plc engages in the development and commercialization of therapeutics for the treatment of respiratory diseases. It focuses on developing inhaled ensifentrine for the maintenance treatment of chronic obstructive pulmonary disease. The company was founded by Michael J. A. Walker and Clive P. Page on February 24, 2005 and is headquartered in London, the United Kingdom.

VRNA
Verona Pharma Plc American Depositary

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest VRNA News

VRNAVerona Pharma Plc American Depositary